Sparsentan (Filspari) is a novel dual endothelin and angiotensin II receptor antagonist, which holds significant clinical value in delaying the decline of renal function in adult patients with primary immunoglobulin A nephropathy (IgAN).

What Are the Purchase Channels for Sparsentan (Filspari)?

Overseas Purchase

Patients may choose to consult and purchase sparsentan at hospital pharmacies or formal drugstores in countries or regions where the medication has been launched.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase Through Medical Service Institutions

Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions can usually provide legal import channels and offer professional consultation and guidance.

Precautions for Purchasing Sparsentan (Filspari)

Strict Medical Evaluation Requirements

Transaminase levels and total bilirubin must be measured before treatment.

Pregnancy status needs to be excluded.

Existing renin-angiotensin-aldosterone system (RAAS) inhibitors and endothelin receptor antagonists must be discontinued.

Professional Medication Guidance Plan

The initial dose is 200 mg taken orally once daily.

After 14 days, the dose is increased to the recommended dose of 400 mg once daily based on tolerability.

Take with meals to reduce gastrointestinal reactions.

The tablets must be swallowed whole and must not be chewed, crushed, or split.

Regular Monitoring Requirements

Monitor ALT and AST once every 3 months.

Regularly assess renal function indicators.

Continuously monitor changes in blood pressure.

Regularly check blood potassium levels.

Authentication of Sparsentan (Filspari) (Genuine vs. Counterfeit)

Identification of Product Appearance Characteristics

200 mg tablets: Film-coated, modified oval-shaped, white to off-white. One side is printed with "105", and the other side is blank.

400 mg tablets: Film-coated, modified oval-shaped, white to off-white. One side is printed with "021", and the other side is blank.

Verification of Packaging Integrity

Supplied in bottles, with 30 tablets per bottle.

Equipped with child-resistant caps.

Clear labeling of storage conditions: 20°C to 25°C.

Confirmation of Official Channels

Filspari is manufactured and distributed by Travere Therapeutics. The packaging should contain complete drug information and approval numbers.